NLS Pharmaceutics Ltd. -CW25NLSPWPreferred / convertible
13F holders, Q3 2024 (September 30)5holders −1
0new positions
1sold out
1famous investor
$0.01avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding NLS Pharmaceutics Ltd. -CW25 (NLSPW) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Altium Capital Management LLC ($2K), Hudson Bay Capital Management LP ($1K) and Citadel Advisors ($224). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- NLS Pharmaceutics Ltd. -CW25
- CUSIP
- H57830111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $368 |
All 13F filers, Q2 2024 → Q3 2024: 3,618 shares bought and 528,394 shares sold, net −524,776 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Altium Capital Management LLC | — | No change | 200,000 | $2K |
| Hudson Bay Capital Management LP | — | Reduce -28.6% | 71,356 | $1K |
| Citadel Advisors | — | Add +22.6% | 19,626 | $224 |
| Armistice Capital, LLC | — | Reduce -97.5% | 12,500 | $143 |
| Clear Street LLC | — | Reduce -0.3% | 8,242 | $94 |
"% of holder's portfolio" is NLSPW's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. -CW25 the manager owns.